Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients

Martin Spahn(Universitätsklinikum Würzburg), Steven Joniau, Steffen Fieuws(Statistics Belgium), Bertrand Tombal(Cliniques Universitaires Saint-Luc), G. Marchioro(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paolo Gontero(Fondazione Ricerca Molinette), Burkhard Kneitz(Universitätsklinikum Würzburg), A Tizzani(University of Turin), D. Frohneberg(Städtisches Klinikum Karlsruhe), Katie Van Der Eeckt, Pia Bader(Städtisches Klinikum Karlsruhe), Chao‐Yu Hsu(National Chung Hsing University)
European Urology
March 10, 2010
10.1016/j.eururo.2010.03.001
Cited by 154

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
|The Lancet|2012|864
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
|European Urology|2015|639
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
|New England Journal of Medicine|2020|442